Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CRNX - US22663K1079 - Common Stock

55.07 USD
+1.83 (+3.44%)
Last: 1/9/2026, 10:43:49 AM
Fundamental Rating

4

Taking everything into account, CRNX scores 4 out of 10 in our fundamental rating. CRNX was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CRNX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRNX had negative earnings in the past year.
CRNX had a negative operating cash flow in the past year.
CRNX had negative earnings in each of the past 5 years.
CRNX had a negative operating cash flow in each of the past 5 years.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

CRNX has a Return On Assets (-35.38%) which is comparable to the rest of the industry.
CRNX's Return On Equity of -39.46% is in line compared to the rest of the industry. CRNX outperforms 56.54% of its industry peers.
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROIC N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRNX has more shares outstanding
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

CRNX has an Altman-Z score of 22.69. This indicates that CRNX is financially healthy and has little risk of bankruptcy at the moment.
CRNX's Altman-Z score of 22.69 is amongst the best of the industry. CRNX outperforms 88.48% of its industry peers.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.69
ROIC/WACCN/A
WACC9.46%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 15.12 indicates that CRNX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 15.12, CRNX belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
CRNX has a Quick Ratio of 15.12. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRNX (15.12) is better than 85.34% of its industry peers.
Industry RankSector Rank
Current Ratio 15.12
Quick Ratio 15.12
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

CRNX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.45%.
Looking at the last year, CRNX shows a very strong growth in Revenue. The Revenue has grown by 47.74%.
The Revenue has been decreasing by -2.68% on average over the past years.
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CRNX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.31% on average per year.
Based on estimates for the next years, CRNX will show a very strong growth in Revenue. The Revenue will grow by 273.06% on average per year.
EPS Next Y-37.76%
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%
EPS Next 5Y22.31%
Revenue Next Year224.94%
Revenue Next 2Y482.25%
Revenue Next 3Y384.21%
Revenue Next 5Y273.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRNX. In the last year negative earnings were reported.
Also next year CRNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRNX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (1/9/2026, 10:43:49 AM)

55.07

+1.83 (+3.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners115.45%
Inst Owner Change0%
Ins Owners1.71%
Ins Owner Change3.94%
Market Cap5.23B
Revenue(TTM)1.53M
Net Income(TTM)-423.10M
Analysts83.64
Price Target81.75 (48.45%)
Short Float %15.48%
Short Ratio11.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.77%
Min EPS beat(2)-9.79%
Max EPS beat(2)-7.76%
EPS beat(4)1
Avg EPS beat(4)-5.74%
Min EPS beat(4)-9.79%
Max EPS beat(4)2.94%
EPS beat(8)1
Avg EPS beat(8)-6.07%
EPS beat(12)1
Avg EPS beat(12)-6.18%
EPS beat(16)2
Avg EPS beat(16)-6.92%
Revenue beat(2)1
Avg Revenue beat(2)310.54%
Min Revenue beat(2)-61.44%
Max Revenue beat(2)682.52%
Revenue beat(4)2
Avg Revenue beat(4)202.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)682.52%
Revenue beat(8)3
Avg Revenue beat(8)91.58%
Revenue beat(12)7
Avg Revenue beat(12)151.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.98%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)-5.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.56%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-7.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3404.29
P/FCF N/A
P/OCF N/A
P/B 4.87
P/tB 4.87
EV/EBITDA N/A
EPS(TTM)-4.53
EYN/A
EPS(NY)-5.4
Fwd EYN/A
FCF(TTM)-3.75
FCFYN/A
OCF(TTM)-3.69
OCFYN/A
SpS0.02
BVpS11.3
TBVpS11.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.38%
ROE -39.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.7%
ROA(5y)-34.4%
ROE(3y)-38.05%
ROE(5y)-38.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 171.91%
Cap/Sales 412.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.12
Quick Ratio 15.12
Altman-Z 22.69
F-Score3
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)244.79%
Cap/Depr(5y)160.44%
Cap/Sales(3y)173.94%
Cap/Sales(5y)166.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.75%
EPS Next Y-37.76%
EPS Next 2Y-20.69%
EPS Next 3Y-0.83%
EPS Next 5Y22.31%
Revenue 1Y (TTM)47.74%
Revenue growth 3Y-1.28%
Revenue growth 5Y-2.68%
Sales Q2Q%N/A
Revenue Next Year224.94%
Revenue Next 2Y482.25%
Revenue Next 3Y384.21%
Revenue Next 5Y273.06%
EBIT growth 1Y-55.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.55%
EBIT Next 3Y-3.6%
EBIT Next 5YN/A
FCF growth 1Y-113.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.54%
OCF growth 3YN/A
OCF growth 5YN/A

CRINETICS PHARMACEUTICALS IN / CRNX FAQ

What is the ChartMill fundamental rating of CRINETICS PHARMACEUTICALS IN (CRNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRNX.


Can you provide the valuation status for CRINETICS PHARMACEUTICALS IN?

ChartMill assigns a valuation rating of 0 / 10 to CRINETICS PHARMACEUTICALS IN (CRNX). This can be considered as Overvalued.


What is the profitability of CRNX stock?

CRINETICS PHARMACEUTICALS IN (CRNX) has a profitability rating of 1 / 10.